INBX

In the past six months, Inhibrx Biosciences' stock has seen significant movements, including a 169.20% increase over the last year, but more recently a decrease of about 4% over the last week and a 21.96% to 23.07% fall in the past month. Key events impacting the stock price include positive interim Phase 2 results for INBRX-106 in combination with pembrolizumab for first-line HNSCC, the U.S. FDA's acceptance of the Biologics License Application (BLA) for ozekibart in patients with conventional chondrosarcoma in June 2026, an amended loan agreement with Oxford Finance in July 2026 expanding its total facility to $500.0 million, and the reporting of its first-quarter 2026 financial results in May 2026 and second-quarter 2026 financial results in August 2026.